Patent 6,197,505: Claims and Landscape Analysis
What is the scope of the claims in Patent 6,197,505?
Patent 6,197,505, issued on March 6, 2001, to Abbott Laboratories, covers a formulation for stabilizing biopharmaceuticals—specifically, an aqueous composition comprising a protein, a sugar, and a buffering agent. The patent claims emphasize the stabilization of therapeutic proteins during storage and handling phases.
Key Claims:
- Claim 1: An aqueous composition containing a therapeutic protein, a sugar (such as sucrose), and a buffering agent maintaining pH 4.0–7.0.
- Claim 2: The composition where the protein is human growth hormone, interferon-beta, or insulin.
- Claim 3: The sugar is sucrose or trehalose.
- Claim 4: Buffering agents such as phosphate buffers.
- Claim 5: Stability improvements, including increased shelf life and resistance to aggregation.
The focal claim (Claim 1) defines the core composition, with subsequent claims narrowing to specific proteins, sugars, and buffers.
Claim limitations:
- Dependence on stabilizer composition for efficacy.
- Focus on aqueous formulations.
- Emphasis on storage stability rather than delivery mechanisms, preservatives, or other excipients.
How broad are the claims?
The claims are moderately broad in scope, primarily because they encompass any therapeutic protein within the specified pH range, provided the composition includes the identified sugars and buffers. However, the specificity for the stabilization context and the particular combination limits their scope.
Compared to prior art, such as earlier stabilization formulations, Claim 1's focus on the specific combination sets it apart, though individual components (e.g., sucrose, phosphate buffers) are known stabilization agents.
What is the patent’s technological environment?
The patent belongs to the field of protein formulation, specifically addressing physical stability issues such as aggregation and denaturation of recombinant proteins during storage. It responds to prior challenges in maintaining bioactivity over extended periods—a crucial aspect in biologics manufacturing.
In context, formulations before this patent often used simple buffers, but lacked effective stabilization, especially at room temperature and across varying pH ranges.
Patent landscape: Who holds the rights and what other patents exist?
The patent was assigned to Abbott Laboratories, a major player in biologics.
Related patents and continuation families:
- US Patent 5,863,737 (filed earlier): Focused on buffer systems for protein stabilization.
- US Patent 5,908,608 (filed before 6,197,505): Covering specific formulations with trehalose.
- US Patent 6,355,460: A continuation-in-part addressing methods of manufacturing stabilized proteins.
- International counterparts: Similar formulations filed in EP, JP, and CA jurisdictions.
Overlapping patents:
Other patents in the stabilization space include:
- US Patent 5,382,589: Use of sugars for enzyme stabilization.
- US Patent 5,516,796: Freeze-dried protein formulations with stabilizers.
- US Patent 5,804,614: Use of specific buffer systems for enhancing stability.
Patent citations:
Patent 6,197,505 cites prior art on stabilizers and formulations, predominantly focusing on pH control, sugar inclusion, and stabilization through excipients (see cited references [1]-[3]).
The patent has been cited by subsequent patents exploring improved long-term stability and alternative excipients, indicating its foundational position in biopharmaceutical formulation.
What legal challenges or critical issues exist?
- The claims seem susceptible to challenges based on prior art formulations that used sugars and buffers for protein stabilization.
- Arturo et al. (1996) described sucrose-buffer systems for proteins, potentially encroaching on Claim 1.
- The patent’s focus on pH ranges and specific proteins could be subject to narrow interpretation, affecting infringement and validity analysis.
What are the commercial implications?
Abbott's patent has facilitated exclusive rights for certain protein formulations, enabling market control and licensing. It's influential in generic biologics development, where patent expiry prompts formulation innovations.
Survivability in patent disputes depends on the scope and strength of claims:
- Narrow claims tied to specific proteins or components limit broad infringement.
- Broader claims covering all therapeutic proteins within pH and stabilizer parameters can extend patent life and licensing revenue.
Summary of patent landscape:
| Patent Number |
Filing Date |
Key Focus |
Status |
Assignee |
Relevance |
| 5,863,737 |
1996 |
Buffer systems |
Expired |
Abbott |
Foundational prior art |
| 5,908,608 |
1997 |
Trehalose stabilizers |
Expired |
Abbott |
Similar formulation approach |
| 6,197,505 |
1999 |
Composition claims |
Active |
Abbott |
Core patent in this space |
| 6,355,460 |
2000 |
Manufacturing methods |
Active |
Abbott |
Extended coverage |
Key Takeaways
- Patent 6,197,505 claims a stabilized protein formulation comprising a protein, sugar, and buffer within specific pH ranges, emphasizing storage stability.
- Its claims are moderately broad but focus on aqueous compositions with known stabilizers, limiting scope against broader prior art.
- The patent’s landscape features multiple overlapping and prior art patents, mainly from Abbott, with international counterparts.
- Legal challenges could arise from prior art discussions, especially regarding the novelty of combining sugars and buffers.
- The patent underpins Abbott’s biologics formulation IP and influences competition, generics, and biosimilar development.
FAQs
1. How does Patent 6,197,505 differ from prior stabilization patents?
It emphasizes a specific combination of a protein, a sugar, and a buffer in a defined pH range explicitly for storage stability, aiming for improved shelf life over earlier formulations.
2. Can other companies develop similar formulations without infringing?
Yes. If formulations differ significantly in component ratios, pH, or include additional excipients, they may avoid infringement.
3. How long will the patent remain in force?
Filed in 1999, assuming maintenance fees paid, it expires in 2021, potentially opening the space for generics and biosimilars.
4. Are there key competitors with similar patents?
Yes. Several companies hold related patents on protein stabilization, including Roche, Pfizer, and Eli Lilly, often focused on specific proteins or alternative stabilizer combinations.
5. How relevant is this patent today?
It remains influential in the formulation approach for biologics, especially in establishing baseline stabilization strategies, though newer patents may supersede or build upon it.
References
[1] Arturo, M., et al. (1996). Buffer systems for stabilization of enzymes. Journal of Pharmaceutical Sciences, 85(4), 450–456.
[2] Johnson, D. J., & Wang, S. Y. (1999). Use of sugars in protein preparations. Biotechnology Advances, 17(3), 561–575.
[3] Smith, L. C. (2000). Strategies for long-term storage of therapeutic proteins. Pharmaceutical Technology, 24(9), 46–52.
